Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease

Author： Saha Sumona   Wald Arnold  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.11, Iss.6, 2012-11, pp. : 947-957

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treating Inflammatory Bowel Disease During Pregnancy: Risks and Safety of Drug Therapy

By Connell W.   Miller A.  

Drug Safety, Vol. 21, Iss. 4, 1999-10 ,pp. : 311-323

Adis International

Access to resources Recommend Favorite

Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety

By  

Current Molecular Pharmacology, Vol. 3, Iss. 3, 2010-11 ,pp. : 145-152

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?

By  

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 249-260

Bentham Science Publishers

Access to resources Recommend Favorite

The use of medications for inflammatory bowel disease during pregnancy and nursing

By Sauk Jenny   Kane Sunanda  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 11, 2005-09 ,pp. : 1833-1839

Informa Healthcare

Access to resources Recommend Favorite

Mesalazine for the treatment of inflammatory bowel disease

By Criscuoli Valeria  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1669-1678

Informa Healthcare

Access to resources Recommend Favorite